Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
212 hedge funds and large institutions have $3.27B invested in Amicus Therapeutics in 2022 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 67 increasing their positions, 78 reducing their positions, and 27 closing their positions.
246% more call options, than puts
Call options by funds: $11.9M | Put options by funds: $3.45M
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
16% more capital invested
Capital invested by funds: $2.81B → $3.27B (+$457M)
0.57% more ownership
Funds ownership: 108.36% → 108.94% (+0.57%)
4% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 27
2% less funds holding
Funds holding: 217 → 212 (-5)
14% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 78
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$51.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$18M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$17.7M |
| 4 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$16.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$128M |
| 2 |
Jennison Associates
New York
|
-$28.8M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$8.19M |
| 4 |
PA
Perceptive Advisors
New York
|
-$5.44M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$4.01M |
FOLD Hedge Fund Activity: Q2 2022 in Review
212 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2022, worth a combined $3.27B — up 16% from $2.81B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of FOLD and 26 opened new positions — a net loss of 1 holder — while 78 trimmed existing stakes and 67 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $51.9M. The largest seller was Wellington Management Group, cutting an estimated $128M.
- 212 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2022, down from 217 in Q1 2022.
- Funds reported $3.27B of Amicus Therapeutics stock for Q2 2022, up 16% quarter-over-quarter.
- 26 funds opened new Amicus Therapeutics positions in Q2 2022 and 27 closed out, a net change of -1 holder.
- The largest Amicus Therapeutics buyer in Q2 2022 was Avoro Capital Advisors, an estimated $51.9M added.
- The largest Amicus Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $128M sold.
Based on aggregated 13F filings for Q2 2022.